Second, aggressive RCC subtypes with increased PSMA expression on the tumor cell surface may also allow for a theranostic approach by identifying potential therapy candidates by 68Ga/18F-PSMA imaging followed by 177Lu-PSMA treatment 83. This evidence concerns the gene FOLH1 and neoplasm.